GbE was shown to exhibit a wide range of pharmaceutical activities on obesity-related conditions, including HFD-induced obesity, diabetes mellitus, and non-alcoholic fatty liver disease [16,17,18]. Here, GBE1 is linked to metabolic dysfunction-associated steatotic liver disease.